Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Feb 24, 2022 |
signed chap.70 delivered to governor |
Jan 31, 2022 |
returned to senate passed assembly ordered to third reading cal.353 substituted for a8836 |
Jan 31, 2022 |
substituted by s7694 |
Jan 27, 2022 |
advanced to third reading cal.353 |
Jan 25, 2022 |
reported |
Jan 13, 2022 |
referred to health |
Assembly Bill A8836
Signed By Governor2021-2022 Legislative Session
Sponsored By
GOTTFRIED
Archive: Last Bill Status Via S7694 - Signed by Governor
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
Votes
co-Sponsors
Nader Sayegh
2021-A8836 (ACTIVE) - Details
- See Senate Version of this Bill:
- S7694
- Law Section:
- Public Health Law
- Laws Affected:
- Amd §2500-a, Pub Health L (as proposed in A.4572 & S.4316)
2021-A8836 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 8836 I N A S S E M B L Y January 13, 2022 ___________ Introduced by M. of A. GOTTFRIED -- read once and referred to the Committee on Health AN ACT to amend the public health law, in relation to newborn screening for glucose-6-phosphate dehydrogenase deficiency THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Paragraph (j) of subdivision 1 of section 2500-a of the public health law, as added by a chapter of the laws of 2021 amending the public health law relating to newborn screening for adrenoleukodys- trophy and glucose-6-phosphate dehydrogenase deficiency, as proposed in legislative bills numbers A. 4572 and S. 4316, is amended to read as follows: (j) Glucose-6-phosphate dehydrogenase deficiency USING A QUANTITATIVE ENZYMATIC TEST OR OTHER DIAGNOSTIC TEST IN CASES WHERE: THE NEWBORN INFANT PRESENTS WITH HEMOLYTIC ANEMIA, HEMOLYTIC JAUNDICE, OR EARLY-ON- SET INCREASING NEONATAL JAUNDICE, THAT IS, JAUNDICE (BILIRUBIN LEVEL GREATER THAN FORTIETH PERCENTILE FOR AGE IN HOURS) PERSISTING BEYOND THE DAY OF BIRTH THROUGH THE WEEK AFTER BIRTH; THE NEWBORN INFANT HAS BEEN ADMITTED TO THE HOSPITAL FOR JAUNDICE FOLLOWING BIRTH; OR THE BIOLOGICAL PARENT OF THE NEWBORN INFANT INDICATES A FAMILY, RACIAL, OR ETHNIC RISK OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY, INCLUDING HAVING SIGNIFICANT AFRICAN, ASIAN, MEDITERRANEAN, OR MIDDLE EASTERN ANCESTRY. § 2. This act shall take effect on the same date and in the same manner as a chapter of the laws of 2021 amending the public health law relating to newborn screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency, as proposed in legislative bills numbers A. 4572 and S. 4316, takes effect. Effective immediately, the commissioner of health shall make regulations and take other actions reasonably necessary to implement this act on that date. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD00136-02-2
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.